Version 2 2020-05-06, 13:13Version 2 2020-05-06, 13:13
Version 1 2019-11-15, 12:07Version 1 2019-11-15, 12:07
journal contribution
posted on 2020-05-06, 13:13authored byHéctor Carreño Gutiérrez, Irene Vacca, Gido Schoenmacker, Madeleine Cleal, Anna Tochwin, Bethan O'connor, Andrew M. J. Young, Alejandro Arias Vasquez, Mathew J. Winter, Matthew O. Parker, William H. J. Norton
Although aggression is a common symptom of psychiatric disorders the drugs available to treat it are non-specific and can have unwanted side effects. In this study we have used a behavioural platform in a phenotypic screen to identify drugs that can reduce zebrafish aggression without affecting locomotion. In a three tier screen of ninety-four drugs we discovered that caffeine and sildenafil can selectively reduce aggression. Caffeine also decreased attention and increased impulsivity in the 5-choice serial reaction time task whereas sildenafil showed the opposite effect. Imaging studies revealed that both caffeine and sildenafil are active in the zebrafish brain, with prominent activation of the thalamus and cerebellum evident. They also interact with 5-HT neurotransmitter signalling. In summary, we have demonstrated that juvenile zebrafish are a suitable model to screen for novel drugs to reduce aggression, with the potential to uncover the neural circuits and signalling pathways that mediate such behavioural effects.
Funding
Seventh Framework Programme (FP7/2007–2013) under grant agreement no.602805
History
Citation
European Neuropsychopharmacology
Volume 30, January 2020, Pages 17-29
Author affiliation
Department of Neuroscience, Psychology and Behaviour
Version
VoR (Version of Record)
Published in
European Neuropsychopharmacology
Volume
39
Pagination
17-29
Publisher
Elsevier for European College of Neuropsychopharmacology